Public Health Groups Close Ranks Against Tobacco Industry

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 10
Volume 6
Issue 10

WASHINGTON-The Administration’s demand that Congress strengthen areas of the proposed tobacco agreement (see article above) won praise from a number of organizations that had criticized the initial settlement as too weak. “The opportunity to enact the right tobacco policy has never been greater,” said John R. Seffrin, PhD, chief executive officer of the American Cancer Society.

WASHINGTON—The Administration’s demand that Congress strengthen areas of the proposed tobacco agreement (see article above) won praise from a number of organizations that had criticized the initial settlement as too weak. “The opportunity to enact the right tobacco policy has never been greater,” said John R. Seffrin, PhD, chief executive officer of the American Cancer Society.

The ACS has joined forces with 10 other major national public health organizations to garner grassroots support to help move the proposal through Congress quickly before momentum fades.

ASCO’s Position

The American Society of Clinical Oncology (ASCO), in a statement issued a few days before the President’s address, also called for major changes to strengthen the proposed settlement.

Of special concern is the focus of the $25 billion research fund included in the tobacco settlement. The Society wants to see the fund sponsor a balanced portfolio of basic and clinical research on tobacco-related cancers and other diseases, and install a rigorous, science-based, peer-reviewed system for making grants.

Recent Videos
Two experts are featured in this series.
Two experts are featured in this series.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
2 experts are featured in this series.
2 experts are featured in this series.
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Related Content